Introduction: Oral Janus kinase inhibitors (JAKi) have demonstrated significant promise in hair regrowth for severe alopecia areata. Baricitinib and ritlecitinib are two medications within this class that have been FDA-approved in recent years, with data supporting treatment response over the course of a few months.
Case Presentation: We present the case of a 28-year-old female with alopecia universalis and a Severity of Alopecia Tool (SALT) of 100%, who failed 1 year of baricitinib therapy and was switched to ritlecitinib. She experienced regrowth of vellus hairs on the scalp and some eyebrow hair after 6 months of therapy and subsequent robust growth of terminal hair after 1 year of ritlecitinib and 2 total years of total JAKi therapy. The patient also had regrowth of the eyelashes, eyebrows, and resolution of nail pitting.
Conclusion: The authors aim to report this case to highlight the success of prolonged JAKi therapy for patients with severe refractory alopecia areata and the success of JAKi therapy after failure of a prior JAKi. Dermatologists should consider longer courses of these medications and switching within the class for patients who experience poor response with initial agents. J Drugs Dermatol. 2025;24(3):316-318. doi:10.36849/JDD.8587.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.36849/JDD.8587 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Achievement of Optimal Treatment Targets with Oral Janus Kinase Inhibition in Elderly Patients with Atopic Dermatitis: A Real-world, Multicenter, Retrospective Study.
J Clin Aesthet Dermatol
February 2025
Drs. Desir, Encarnacion, and Mollanazar are with the Department of Dermatology at Perelman School of Medicine at the University of Pennsylvania in Philadelphia, Pennsylvania.
Objective: Oral Janus kinase inhibitors (JAKi) have demonstrated high levels of efficacy with acceptable safety in patients with atopic dermatitis (AD), yet there remains significant hesitancy among the dermatologic community to use JAKi in elderly populations due to the potential increased risk of serious adverse events in this population. We aimed to perform a retrospective review to describe real-world outcomes for the use of selective JAK-1 inhibitors in patients with AD aged 65 years or older.
Methods: We conducted a multicenter retrospective review.
Targeted Therapies in Myelofibrosis: Present Landscape, Ongoing Studies, and Future Perspectives.
Am J Hematol
March 2025
Department of Experimental and Clinical Medicine, CRIMM, Center of Research and Innovation of Myeloproliferative Neoplasms, Azienda Ospedaliero- Universitaria Careggi, University of Florence, Florence, Italy.
Myelofibrosis (MF) is a myeloproliferative neoplasm that is accompanied by driver JAK2, CALR, or MPL mutations in more than 90% of cases, leading to constitutive activation of the JAK-STAT pathway. MF is a multifaceted disease characterized by trilineage myeloid proliferation with prominent megakaryocyte atypia and bone marrow fibrosis, as well as splenomegaly, constitutional symptoms, ineffective erythropoiesis, extramedullary hematopoiesis, and a risk of leukemic progression and shortened survival. Therapy can range from observation alone in lower-risk and asymptomatic patients to allogeneic hematopoietic stem cell transplantation, which is the only potentially curative treatment capable of prolonging survival, although burdened by significant morbidity and mortality.
View Article and Find Full Text PDFLong-term Outcomes of New Systemic Agents in Atopic Dermatitis: Drug Survival Analyses and Treatment Patterns in Daily Practice.
Acta Derm Venereol
March 2025
Department of Dermatology, Erasmus University Medical Center, Rotterdam, The Netherlands.
In recent years, several new systemic agents (biologics and Janus kinase inhibitors [JAKi]) have been registered for the treatment of moderate-to-severe atopic dermatitis (AD). However, comparisons of real-world drug survival data and insights into treatment patterns of these advanced systemics are limited. Data from a prospective observational single-centre registry were collected from 549 adult AD patients (759 treatment courses) receiving biologics (dupilumab, tralokinumab) or JAKi (abrocitinib, baricitinib, upadacitinib) and analysed using Kaplan-Meier survival curves.
View Article and Find Full Text PDFReal-World Effectiveness and Safety of Upadacitinib in Crohn's disease: A Multi-Centre Study.
Clin Gastroenterol Hepatol
March 2025
Division of Gastroenterology, Washington University School of Medicine, Saint Louis, MO. Electronic address:
Background: We aimed to describe the real-world effectiveness and safety of upadacitinib (UPA), an oral Janus kinase 1 inhibitor (JAKi) in patients with Crohn's disease (CD).
Methods: A retrospective analysis was conducted across nine centers in the United States, focusing on adults with CD treated with UPA 45 mg as induction therapy for active luminal disease. The co-primary endpoints were clinical remission at 12 weeks (Harvey Bradshaw Index ≤ 4 or absence of symptoms on physician's global assessment) and endoscopic remission at 6 months (SEMA-CD score of 0-1 or absence of ulcers).
Efficacy and safety profile of biotechnological agents and Janus kinase inhibitors in VEXAS syndrome: data from the international AIDA Network VEXAS registry.
Front Pharmacol
February 2025
Department of Medical Sciences, Surgery and Neurosciences, Research Center of Systemic Autoinflammatory Diseases and Behçet's Disease Clinic, University of Siena, Siena, Italy.
Background: VEXAS syndrome, a recently identified systemic autoinflammatory disorder, poses new diagnostic and management challenges. Based on experience with other autoinflammatory diseases, anti-interleukin (IL)-1, anti-IL-6, anti-tumor necrosis factor (TNF) biotechnological agents, and Janus kinase inhibitors (JAKis) have been widely employed in VEXAS patients. The aim of this study is to evaluate the global effectiveness and safety of biotechnological agents and JAKis using data from the real-world context.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!